As prescription weight-loss medications become more common in American households, Scotland-based consumer wellness company Wolfson Group is drawing attention to the enduring role of nutrition, physical activity and non-prescription products in the broader weight management marketplace. A June 2026 report from PwC found that 21% of U.S. households included a current GLP-1 user as of May 2026, up from 9% in January 2025. That sharp increase underscores how quickly prescription medications have entered the mainstream weight management conversation, but Wolfson Group argues that consumers are simultaneously navigating a diverse array of nutritional products, fitness programs and lifestyle resources.
Wolfson Group participates in the non-prescription category through PhenQ, its established consumer wellness brand, which is available to U.S. consumers through Amazon and, more recently, OneLavi.com. The company emphasizes that PhenQ is a non-prescription product and should not be viewed as a substitute for prescribed medical treatments.
“The weight management market is evolving, and consumers have more choices than ever before,” said the founder and CEO of Wolfson Group. “Prescription medications have become an important part of the conversation, but nutrition, physical activity and everyday lifestyle habits remain central to how people think about managing their weight. Our focus is on serving consumers in the non-prescription wellness market.”
The growing visibility of GLP-1 medications has brought renewed attention to weight management across the United States, and Wolfson Group believes this evolving landscape creates opportunities for greater consumer education about the different categories of products and services available, their intended purposes and the importance of making informed decisions. The company stresses that non-prescription wellness products and prescription medications are distinct categories.
As consumer interest in weight management continues, Wolfson Group is expanding the availability of PhenQ through additional U.S. retail channels. Beyond its established presence on Amazon and its recent launch on OneLavi.com, the company continues to pursue broader retail opportunities following its participation in the September ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida. The expansion reflects Wolfson Group’s broader U.S. strategy of developing multiple distribution channels while supporting its portfolio of established wellness brands.
Wolfson Group’s portfolio spans weight management, cognitive wellness, gut health and men’s wellbeing, including brands such as PhenQ, TestoPrime, NooCube and YourBiology. The company said it will continue investing in consumer education, science-led brand development and expanded U.S. distribution as it builds its presence across the American wellness marketplace. For readers, the takeaway is a market in transition: prescription options are growing rapidly, but non-prescription brands are also adapting, and clear information about product categories remains essential for informed decision-making.
